Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer With Deficient Mismatch Repair System Post PD1 Exposure
NCT04197219Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of axitinib in endometrial cancer (EC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 12 weeks. Planned start Feb 2021; status: withdrawn.
02
Drugs
axitinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04197219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197219.